| Autor: |
Marlene Reincke, Michael Schultheiss, Michael Doppler, Niklas Verloh, Wibke Uller, Lukas Sturm, Robert Thimme, Christian Goetz, Dominik Bettinger |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Hepatology Communications, Vol 6, Iss 11, Pp 3223-3233 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2471-254X |
| DOI: |
10.1002/hep4.2072 |
| Popis: |
Abstract Transarterial radioembolization (TARE) is a well‐established therapy for intermediate and advanced tumor stages of hepatocellular carcinoma (HCC). Treatment‐associated toxicities are rare. Previous studies have outlined that the prognosis after TARE is determined primarily by tumor stage and liver function. The subset of patients benefiting from TARE remains to be defined. Sixty‐one patients with HCC treated with TARE between 2015 and 2020 were retrospectively included in the study. Hepatic decompensation was defined as an increase of bilirubin or newly developed ascites that was not explained by tumor progression within 3 months after TARE. Predictive factors of hepatic decompensation and prognostic factors were assessed. Hepatic decompensation was observed in 27.9% (n = 17) of TARE‐treated patients during follow‐up. Albumin‐bilirubin (ALBI) score at baseline and radiation dose on nontumor liver proved to be independent risk factors for the development of hepatic decompensation in multivariable regression models (ALBI score: odds ratio [OR] 6.425 [1.735;23.797], p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text